STI571: a gene product-targeted therapy for leukemia.

M. J. Mauro, Brian Druker

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalCurrent Oncology Reports
Volume3
Issue number3
StatePublished - May 2001

Fingerprint

Leukemia
bcr-abl Fusion Proteins
Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Genes
Therapeutics
Hematopoietic Stem Cells
Interferons
Imatinib Mesylate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

STI571 : a gene product-targeted therapy for leukemia. / Mauro, M. J.; Druker, Brian.

In: Current Oncology Reports, Vol. 3, No. 3, 05.2001, p. 223-227.

Research output: Contribution to journalArticle

@article{7c029c88ff7940f5b0eeae8f04a597a1,
title = "STI571: a gene product-targeted therapy for leukemia.",
abstract = "Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.",
author = "Mauro, {M. J.} and Brian Druker",
year = "2001",
month = "5",
language = "English (US)",
volume = "3",
pages = "223--227",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - STI571

T2 - a gene product-targeted therapy for leukemia.

AU - Mauro, M. J.

AU - Druker, Brian

PY - 2001/5

Y1 - 2001/5

N2 - Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.

AB - Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Conventional therapeutic options include interferon-based regimens and stem-cell transplantation, with stem-cell transplantation being the only curative therapy. Through rational drug development, STI571, a bcr-abl tyrosine kinase inhibitor, has emerged as a paradigm for gene product-targeted therapy, offering new hope for expanded treatment options for patients with CML.

UR - http://www.scopus.com/inward/record.url?scp=0035344667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035344667&partnerID=8YFLogxK

M3 - Article

C2 - 11296132

AN - SCOPUS:0035344667

VL - 3

SP - 223

EP - 227

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 3

ER -